Karen S. Gustafson, MD, PhD
Associate Professor of Clinical Pathology and Laboratory Medicine
Perelman School of Medicine at the University of Pennsylvania
Contact InformationHospital of the University of Pennsylvania
6 Founders, Room FO6.042
3400 Spruce Street
Philadelphia, PA 19104
Office: 215-662-3209
Email: Karen.Gustafson@pennmedicine.upenn.edu
Specialty Division
Anatomic Pathology
Education
B.A. (Biology and Chemistry), Gustavus Adolphus College, 1983
MD, PhD (Biomedical Science), University of Minnesota Medical Scientist Training Program, 1998
Specialty Certification
American Board of Pathology, Anatomic and Clinical Pathology, 2002
American Board of Pathology, Cytopathology, 2004
American Board of Pathology, Recertification, 2014
Postgraduate Training
Intern, Anatomic and Clinical Pathology, Department of Pathology and Laboratory Medicine
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 1998-1999
Resident, Anatomic and Clinical Pathology, Department of Pathology and Laboratory Medicine
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 1999-2002
Chief Resident- Anatomic Pathology, Hospital of the University of Pennsylvania, 2001-2002
Fellow, Surgical Pathology, Department of Pathology and Laboratory Medicine
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 2002-2003
Cytopatholgy Fellow, Department of Pathology and Laboratory Medicine
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 2003-2004
Awards and Honors
Phi Beta Kappa, Gustavus Adolphus College, 1983
Phi Kappa Phi, University of Minnesota, 1994
Alpha Omega Alpha, University of Minnesota Medical School, 1997
J. Jacob Kaplan Award, University of Minnesota Medical School, 1997
H.T. Enterline Fellowship in Surgical Pathology Award, Hospital of the University of Pennsylvania, 2003
Geno Saccomanno, M.D. New Frontiers in Cytology Award, American Society of Cytopathology, 2009
Leadership Forum Excellence Recognition Award, Fox Chase Cancer Center, 2012
Memberships and Professional Organizations
College of American Pathologists, 2000 - Present
United States and Canadian Academy of Pathology, 2000 - Present
American Society of Clinical Pathologists, 2000 - 2004
Papanicolaou Society of Cytopathology, 2002 - Present
American Society of Cytopathology, 2003 - Present
American Society of Cytopathology, 2007 - 2008
American Society of Cytopathology, 2008 - 2010
Association for Molecular Pathology, 2010 - Present
Web Links
Selected Publications
Asymptomatic bilateral facial swelling
Almasri B, Gustafson KS, Husson MA, Shanti RM, France K, J Am Dent Assoc 154(3): 260-265, 2023, PMID:35341561
Role of Ancillary Techniques in Fluid Cytology
Yu GH, Glaser LJ, Gustafson KS, Acta Cytologica 64(): 52-62, 2020
Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: A Fox Chase Cancer Center pilot study.
Vijayvergia, N., Boland, P. M., Handorf, E., Gustafson, K. S., Gong, Y., Cooper, H. S., Sheriff, F., Astsaturov, I. A., Cohen, S. J., Engstrom, P. F., British Journal of Cancer 115(5): 564-570, 2016, PMID:27482646
Tumor genomic profiling (TGP) in metastatic colorectal cancer (CRC): Bridging the community and the tertiary cancer center through genomic consultation (GC).
Kaczmar, J.M., Gustafson, K.S., Wong, Y.N., Minniti, C.J., Sandilya, V.K., Sprandio, J.D., Chertock, Y., Hart, C., Hall, M.J., Journal of Clinical Oncology 34(4): , 2016
Molecular profiling and clinical outcomes in malignant melanoma: Experience at a NCI-designated cancer center.
Zih, F.S., Kulkarni, N., Escalante, D.A., Meade, C., Osevala, N., Zibelman, M., Movva, S., Gustafson, K.S., Wu, H., Reddy, S., Lango, M., Olszanski, A.J., Farma, J., Annals of Surgical Oncology 23(): , 2016
Molecular profiling and clinical outcomes in patients with in-transit recurrence of melanoma.
Farma, J., Kulkarni, N., Escalante, D.A., Meade, C., Osevala, N., Zibelman, M., Gustafson, K.S., Wu, H., Lango, M., Reddy, S., Movva, S., Olszanski, A.J., Zih, F.S., Annals of Surgical Oncology 23(): , 2016
Molecular profiling defines subsets of neuroendocrine tumors (NETs) with aggressive disease: A Fox Chase Cancer Center (FCCC) study.
Vijayvergia, N., Cohen, S.J., Boland, P.M., Gustafson, K.S., Sherrif, F., Cooper, H., Astaturov, I., Engstrom, P.F., Pancreas 45(3): 469-470, 2016
CSI: Cancer Signature Investigation: ERBB2 (HER2)-activating mutation and amplification-positive breast carcinoma mimicking lung primary.
Shih J, Bashir B, Gustafson KS, Andrake MA, Dunbrack RL, Goldstein LJ, Boumber Y., J Natl Compr Canc Netw 13(8): 947-52, 2015, PMID:26285240
Molecular profiling of neuroendocrine tumors (NETs): The Fox Chase Cancer Center (FCCC) experience.
Vijayvergia, N., Boland, P. M., Cohen, S. J., Gustafson, K. S., Cooper, H. S., Astsaturov, I. A., Engstrom, P. F., Journal of Clinical Oncology 33(3): , 2015
Molecular profiling of advanced stage neuro endocrine tumors (NETs): The Fox Chase Cancer Center (FCCC) experience.
Vijayvergia, N., Boland, P. M., Gustafson, K. S., Sheriff, F., Cooper, H. S., Cohen, S. J., Astsaturov, I. A., Engstrom, P. F., Pancreas 44(2): , 2015
